Lead Product(s) : Sangivamycin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : University of Alberta
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The research collaboration is focused on the development and testing of TNX-3500 (sangivamycin), Wnt/β-Catenin signaling pathway inhibitors as broad-spectrum antivirals against SARS-CoV-2 and other emerging viruses.
Brand Name : TNX-3500
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 18, 2022
Lead Product(s) : Sangivamycin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : University of Alberta
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Sangivamycin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Tonix Pharmaceuticals Holding Corp
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Tonix has been granted an exclusive license from OyaGen for technology and patents related to TNX-3500 and other related compounds.
Brand Name : TNX-3500
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 19, 2021
Lead Product(s) : Sangivamycin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Tonix Pharmaceuticals Holding Corp
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Sangivamycin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The study results showed that OYA1 was "highly effective" in reducing the spread of Ebola Virus infection in laboratory tests with the live Ebola virus carried out by NIAID. The data also suggest that OYA1 could be significantly more potent than Gilead ...
Brand Name : OYA1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 07, 2021
Lead Product(s) : Sangivamycin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?